Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN
- PMID: 17560336
- DOI: 10.1016/j.ccr.2007.04.021
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN
Abstract
Although most oncogenic phenotypes of PTEN loss are attributed to AKT activation, AKT alone is not sufficient to induce all of the biological activities associated with PTEN inactivation. We searched for additional PTEN-regulated pathways through gene set enrichment analysis (GSEA) and identified genes associated with JNK activation. PTEN null cells exhibit higher JNK activity, and genetic studies demonstrate that JNK functions parallel to and independently of AKT. Furthermore, PTEN deficiency sensitizes cells to JNK inhibition and negative feedback regulation of PI3K was impaired in PTEN null cells. Akt and JNK activation are highly correlated in human prostate cancer. These findings implicate JNK in PI3K-driven cancers and demonstrate the utility of GSEA to identify functional pathways using genetically defined systems.
Similar articles
-
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.Adv Enzyme Regul. 2006;46:249-79. doi: 10.1016/j.advenzreg.2006.01.004. Epub 2006 Jul 18. Adv Enzyme Regul. 2006. PMID: 16854453
-
PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.Oncogene. 2002 Aug 8;21(34):5289-300. doi: 10.1038/sj.onc.1205650. Oncogene. 2002. PMID: 12149650
-
Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.Cancer Res. 2005 Aug 1;65(15):6601-11. doi: 10.1158/0008-5472.CAN-04-4184. Cancer Res. 2005. PMID: 16061640
-
PTEN, more than the AKT pathway.Carcinogenesis. 2007 Jul;28(7):1379-86. doi: 10.1093/carcin/bgm052. Epub 2007 Mar 6. Carcinogenesis. 2007. PMID: 17341655 Review.
-
The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review).Int J Oncol. 2015 Aug;47(2):429-36. doi: 10.3892/ijo.2015.3052. Epub 2015 Jun 16. Int J Oncol. 2015. PMID: 26082006 Review.
Cited by
-
A novel biomarker GATM suppresses proliferation and malignancy of cholangiocarcinoma cells by modulating the JNK/c-Jun signalling pathways.Heliyon. 2024 Sep 3;10(17):e37344. doi: 10.1016/j.heliyon.2024.e37344. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39296238 Free PMC article.
-
JunB and PTEN in prostate cancer: 'loss is nothing else than change'.Cell Death Differ. 2015 Apr;22(4):522-3. doi: 10.1038/cdd.2014.232. Cell Death Differ. 2015. PMID: 25747853 Free PMC article. No abstract available.
-
Structural and functional analysis of the natural JNK1 inhibitor quercetagetin.J Mol Biol. 2013 Jan 23;425(2):411-23. doi: 10.1016/j.jmb.2012.10.019. Epub 2012 Nov 8. J Mol Biol. 2013. PMID: 23142567 Free PMC article.
-
PPEF/PP7 protein Ser/Thr phosphatases.Cell Mol Life Sci. 2009 Oct;66(19):3103-10. doi: 10.1007/s00018-009-0110-7. Epub 2009 Aug 7. Cell Mol Life Sci. 2009. PMID: 19662497 Free PMC article. Review.
-
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.Blood. 2010 Feb 18;115(7):1406-15. doi: 10.1182/blood-2009-06-229443. Epub 2009 Dec 14. Blood. 2010. PMID: 20008787 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials